MX9700081A - Tacrine pharmaceutical compositions. - Google Patents

Tacrine pharmaceutical compositions.

Info

Publication number
MX9700081A
MX9700081A MX9700081A MX9700081A MX9700081A MX 9700081 A MX9700081 A MX 9700081A MX 9700081 A MX9700081 A MX 9700081A MX 9700081 A MX9700081 A MX 9700081A MX 9700081 A MX9700081 A MX 9700081A
Authority
MX
Mexico
Prior art keywords
tacrine
pharmaceutical compositions
administering
patient
disclosed
Prior art date
Application number
MX9700081A
Other languages
Spanish (es)
Inventor
George V Guittard
Jerry D Childers
Patrick S L Wong
Fernando E Gumucio
David J Kidney
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of MX9700081A publication Critical patent/MX9700081A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy.
MX9700081A 1994-06-27 1995-06-14 Tacrine pharmaceutical compositions. MX9700081A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/266,045 US5698224A (en) 1994-06-27 1994-06-27 Tacrine therapy
PCT/US1995/007726 WO1996000065A1 (en) 1994-06-27 1995-06-14 Tacrine pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX9700081A true MX9700081A (en) 1997-04-30

Family

ID=23012934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700081A MX9700081A (en) 1994-06-27 1995-06-14 Tacrine pharmaceutical compositions.

Country Status (11)

Country Link
US (2) US5698224A (en)
EP (1) EP0768880A1 (en)
JP (1) JPH10507440A (en)
KR (1) KR970703768A (en)
AU (1) AU685297B2 (en)
CA (1) CA2187332A1 (en)
FI (1) FI965202A (en)
MX (1) MX9700081A (en)
NO (1) NO965539L (en)
NZ (1) NZ288951A (en)
WO (1) WO1996000065A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US7049078B2 (en) 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5593769A (en) * 1995-06-14 1997-01-14 Minnesota Mining And Manufacturing Company Polyurethane pad covering for gel filled articles
US6110498A (en) * 1996-10-25 2000-08-29 Shire Laboratories, Inc. Osmotic drug delivery system
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
JP5173089B2 (en) * 1996-11-25 2013-03-27 アルザ コーポレイション Increasing dose drug dosage form
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
KR100603900B1 (en) * 1998-10-01 2006-07-25 노파르티스 아게 New sustained release oral formulations
AU1230800A (en) * 1998-11-02 2000-05-22 Alza Corporation Controlled delivery of antidepressants
RU2246295C2 (en) * 1998-11-02 2005-02-20 Элзэ Копэрейшн Medicinal formulation with constant rate for releasing medicinal substance, core of medicinal formulation and method for providing relieved release of medicinal substance from medicinal formulation
WO2001000215A1 (en) * 1999-06-25 2001-01-04 Wake Forest University Compositions for treating or preventing neurodegeneration and cognitive decline
EP1233761B1 (en) * 1999-11-22 2007-03-28 ALZA Corporation Osmotic dosage form comprising first and second coats
JP2003518487A (en) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク Hydrogel-driven laminated drug formulation
DE60038698T2 (en) * 1999-12-23 2009-05-07 Pfizer Products Inc., Groton HYDROGEL-CONTROLLED DOSAGE FORM
AU2002351008B2 (en) * 2001-11-30 2007-07-12 Pfizer Products Inc. Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
EP1684806B1 (en) * 2003-11-21 2008-06-25 Memory Pharmaceuticals Corporation Compositions comprising l-type calcium channel blockers and cholinesterase inhibitors
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2005116047A2 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
DK1811957T3 (en) * 2004-10-19 2009-03-30 Krka Tovarna Zdravil D D Novo Solid pharmaceutical composition comprising donepezil hydrochloride
WO2006060186A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives for the treatment of dementia and related disorders
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
WO2006106514A2 (en) * 2005-04-06 2006-10-12 Nicast Ltd. Electrospun dosage form and method of producing the same
CA2604617C (en) * 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
JP5095615B2 (en) * 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ Modified release of bupropion salt
EP2258357A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CN101420939A (en) * 2006-04-24 2009-04-29 辉瑞产品公司 Asymmetric membranes for drug delivery devices
WO2008001341A1 (en) * 2006-06-27 2008-01-03 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
CN101703488B (en) * 2008-12-16 2013-02-20 北京科信必成医药科技发展有限公司 Two-layer osmotic pump controlled release tablet with lubricating layer structure and preparation method thereof
US20100173827A1 (en) * 2008-12-16 2010-07-08 Jerzy Alexander Georgiades Role of proline rich peptides in cellular communication mechanisms and treatment of diseases
USD666376S1 (en) 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
USD666377S1 (en) 2010-12-01 2012-09-04 Kraft Foods Global Brands Llc Lozenge
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN105030714A (en) * 2015-07-06 2015-11-11 长春中医药大学 Aniracetam sustained release tablet and preparation method thereof
GB201602145D0 (en) 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
USD805726S1 (en) * 2016-03-11 2017-12-26 Mars, Incorporated Pet food
RU2616247C1 (en) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Solid dosage forms with choline-positive action based on 9-butylamino-3,3-dimethyl-1,2,4-trihydroacridine
KR20220044543A (en) * 2019-08-08 2022-04-08 에보니크 오퍼레이션즈 게엠베하 Methods and lubricants for preparing solid dosage forms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
WO1992015285A1 (en) * 1991-03-01 1992-09-17 Warner-Lambert Company Starch-based controlled release compositions
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
WO1995003052A1 (en) * 1993-07-22 1995-02-02 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
EP0788793A1 (en) * 1996-02-01 1997-08-13 Takeda Chemical Industries, Ltd. Idebenone for the treatment of dementia

Also Published As

Publication number Publication date
NZ288951A (en) 1997-04-24
US6036973A (en) 2000-03-14
FI965202A0 (en) 1996-12-23
AU2864495A (en) 1996-01-19
US5698224A (en) 1997-12-16
NO965539L (en) 1997-02-25
FI965202A (en) 1996-12-23
AU685297B2 (en) 1998-01-15
NO965539D0 (en) 1996-12-23
KR970703768A (en) 1997-08-09
WO1996000065A1 (en) 1996-01-04
JPH10507440A (en) 1998-07-21
CA2187332A1 (en) 1996-01-04
EP0768880A1 (en) 1997-04-23

Similar Documents

Publication Publication Date Title
MX9700081A (en) Tacrine pharmaceutical compositions.
GR1000932B (en) Dosage form for administering oral hupoglycemic glipizide
ZA913282B (en) Dosage form
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
IL91656A0 (en) Pharmaceutical composition containing a benzodiazepine derivative
DK0600079T3 (en) Oral 1alpha-hydroxypravitamin D
IL123889A0 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
YU49026B (en) THE USE OF 17 ß -(N-TERT-BUTYLCARBAMOYIL)-4-AZA-5-ALPHA-ANDROST-1-ENE-3-ONE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ANDROGENIC ALOPECIA
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
GR3034186T3 (en) 3,4-diarylchromans for treatment of dermatitis
ES2026304A6 (en) Dosage form for administering calcium antagonist.
GB9727131D0 (en) Therapeutic agents
MY124465A (en) Reduction of infarct volume using citicoline
GR3032041T3 (en) Idebenone compositions for treating Alzheimer's disease.
NO974486L (en) Low-dose "Ridogrel" formulations and their use in the treatment of intestinal inflammation
PH31582A (en) Glycoslated cytokins.
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
DE3369327D1 (en) Pharmaceutical compounds, preparation, use and intermediates therefor and their preparation
BG102266A (en) Method for the preparation of solid batched forms having very low doses of the medicamentous form
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
RU99112967A (en) METHOD FOR TREATMENT AND PREVENTION OF PIG DYSENTERY
UA15281A (en) Method for treatment of chronic coronary heart disease
UA30251A (en) The method for treatment of oddis sphincter hypertonia for patients with chronic acalculous cholecystitis along with hypersympathicotonia
MY110769A (en) Controlled release oxycodone compositions.
AU5912794A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs